Completed PHASE3 INTERVENTIONAL 3-arm NCT00541489

Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Hip

A 13-Week, Phase 3, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo Bid and Naproxen 500 mg Bid, Controlled Study on the Efficacy on Signs and Symptoms, and Safety of Naproxcinod (HCT3012) 750 mg Bid, in Patients With Osteoarthritis of the Hip

Sponsor: NicOx

Conditions Osteoarthritis Osteoarthritis, Hip

Interventions Naproxcinod Naproxen Placebo

Updated 6 times since 2017 Last updated: Feb 19, 2009 Started: Jun 30, 2007 Primary completion: Sep 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Osteoarthritis and Osteoarthritis, Hip, this trial is completed. The trial is conducted by NicOx and has accumulated 6 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NicOx

Data source: NicOx

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anderson, United States , Austin, United States , Berlin, United States , Bethany, United States , Burnaby, Canada , Chandler, United States , Cincinnati, United States , Cleveland, United States , Columbia, United States , Coquitlam, Canada and 38 more locations